MiR-200c-3p suppression is associated with development of acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutant non-small cell lung cancer via a mediating epithelial-to-mesenchymal transition (EMT) process
Journal
Cancer biomarkers : section A of Disease markers
Date Issued
2020-05-09
Author(s)
Wang, Hsin-Yi
Liu, Yi-Nan
HSU, CHIA-LANG
Chang, Tzu-Hua
Tsai, Meng-Feng
Abstract
EGFR-mutant lung cancer inevitably develops resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
Subjects
Erlotinib; gefitinib; miR-200c-3p; miR-203a-3p; non-small cell lung cancer; tyrosine kinase inhibitors
SDGs
Other Subjects
epidermal growth factor receptor; erlotinib; gefitinib; microRNA; microRNA 200c 3p; microRNA 203a 3p; unclassified drug; EGFR protein, human; epidermal growth factor receptor; microRNA; MIRN200 microRNA, human; protein kinase inhibitor; adult; aged; Article; cancer survival; carcinogenesis; cell death; cell migration; controlled study; down regulation; drug efficacy; drug resistance; epithelial mesenchymal transition; female; gene expression profiling; gene function; gene mutation; gene overexpression; gene repression; gene silencing; human; human tissue; lung adenocarcinoma; major clinical study; male; malignant pleura effusion; mRNA expression level; non small cell lung cancer; polymerase chain reaction; priority journal; progression free survival; treatment outcome; treatment response; drug effect; drug resistance; epithelial mesenchymal transition; follow up; gene expression regulation; genetics; Kaplan Meier method; lung; lung resection; lung tumor; malignant pleura effusion; metabolism; middle aged; mortality; mutation; non small cell lung cancer; pathology; surgery; tumor cell line; very elderly; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Pleural Effusion, Malignant; Pneumonectomy; Progression-Free Survival; Protein Kinase Inhibitors
Type
journal article